Takara has been granted a patent for a method to deplete target nucleic acids from a collection. By using cleavage-deficient nucleases and guide nucleic acids, the method selectively separates target nucleic acids from non-target ones. This innovation opens new possibilities in nucleic acid research and diagnostics. GlobalData’s report on Takara gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Takara, Anti-viral antigen-based compositions was a key innovation area identified from patents. Takara's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Selective separation of target nucleic acids from a composition
See Also:
A recently granted patent (Publication Number: US11884963B2) discloses a method for selectively separating target nucleic acids from a composition. The method involves contacting the composition with cleavage-deficient nucleases and guide nucleic acids to form a complex where the guide nucleic acids specifically hybridize with the target nucleic acids. This complex is then separated from the composition, effectively isolating the target nucleic acids from non-target nucleic acids. The patent claims cover various aspects of the method, including the types of target nucleic acids, guide nucleic acids, and cleavage-deficient nucleases used in the process.
The patent also describes a method for producing a composition selectively enriched with target nucleic acids. Similar to the previous method, this process involves contacting the composition with cleavage-deficient nucleases and guide nucleic acids to form a complex that is then separated from the composition. The target nucleic acids can be double-stranded nucleic acids, cDNA, DNA, RNA, or a combination thereof. The guide nucleic acids can be RNA or DNA, with specific examples provided in the claims. Additionally, the cleavage-deficient nucleases used in the method can include Cas nucleases, Argonaute nucleases, or a combination of both, with the complex being separated from the composition by immobilization on a solid phase using specific tags. The patent covers various embodiments and applications of the method for selectively enriching target nucleic acids in a composition.
To know more about GlobalData’s detailed insights on Takara, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
